. Author manuscript; available in PMC: 2015 Feb 1.

Published in final edited form as: Cancer. 2013 Oct 22;120(3):373–380. doi: 10.1002/cncr.28433

Table 2.

Responses to Therapy by used TKI.

	N (%)
	Overall (n=42)	Imatinib (n=27)	Dasatinib (n=15)
Complete Hematological Remission (CHR)	38 (90)	23 (85)	15 (100)
Complete Cytogenetic Remission (CCyR)	24 (59)	11 (41)	13 (87)
Complete Molecular Remission (CMR)	8/32 (25)	7/18 (39)	1/14 (7)^*
Major Molecular Remission (MMR)	16/32 (50)	8/18 (44)	8/14 (57)
Minimal Residual Disease (MRD) negative by FC	7/12 (58)	2/5 (40)	5/7 (71)

among patients achieving MMR, SCT was performed before CMR achievement in 4/8 (50%) of patients on dasatinib and 1/8 (12%) of patients on imatinib.